Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | DRD4 | P21917 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | LTA4H | P09960 | 1/20 | 0.60 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | MC4R | P32245 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4293243 | 0.90 | DRD2 (0.55) | CYP2D6DRD2DRD4DRD3LTA4H | |
| SCHEMBL14716240 | 0.87 | CYP2D6 (0.63) | CYP2D6DRD2DRD4DRD3LTA4H | |
| SCHEMBL14081425 | 0.84 | CYP2D6 (0.56) | CYP2D6DRD2DRD4DRD3OPRL1 | |
| SCHEMBL15505949 | 0.84 | HDAC1 (0.58) | CYP2D6DRD2DRD4DRD3LTA4H | |
| SCHEMBL3566447 | 0.84 | SLC6A3 (0.54) | CYP2D6CHRM2SIGMAR1TSHRMEN1 | |
| SCHEMBL8809190 | 0.82 | CYP3A4 (0.66) | CYP2D6DRD2DRD4DRD3CHRM2 | |
| SCHEMBL13556689 | 0.81 | CYP2D6 (0.60) | CYP2D6CYP3A4HSD17B10ALDH1A1TSHR | |
| SCHEMBL1991966 | 0.81 | CYP2D6 (0.59) | CYP2D6DRD2DRD4DRD3OPRL1 | |
| SCHEMBL1147211 | 0.81 | OPRL1 (0.63) | CYP2D6OPRL1CHRM2CHRM3CYP3A4 | |
| SCHEMBL2158292 | 0.81 | DRD2 (0.53) | CYP2D6DRD2DRD4DRD3OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105263490-B | Substituted triazolopyridines and methods of use | 基因泰克公司 | 2018-05-22 | — | — | CN | disclosed |
| CN-105263490-A | Substituted triazolopyridines and methods of use | GENENTECH INC | 2016-01-20 | — | — | CN | disclosed |
| US-20130281476-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
| US-8367691-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
| EP-2513110-A1 | 1, 7 - DIAZACARBAZOLES AND THEIR USE IN THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| US-8263605-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-09-11 | — | — | US | disclosed |
| US-8258148-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-09-04 | — | — | US | disclosed |
| EP-1817036-B1 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMA (US) | 2012-07-04 | — | — | EP | disclosed |
| WO-2007100670-A1 | SPIRO CONDENSED PIPERIDNES AS MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-07 | — | — | WO | disclosed |
| CN-101031296-A | Modulators of muscarinic receptors | VERTEX PHARMA (US) | 2007-09-05 | — | — | CN | disclosed |
| EP-1817036-A2 | MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmaceuticals Incorporated (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2007076070-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1781288-A2 | MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmaceuticals Incorporated (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20070043023-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| US-20060270653-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2006-11-30 | — | — | US | disclosed |
| WO-2006058303-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-01 | — | — | WO | disclosed |
| US-20060079505-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2006-04-13 | — | — | US | disclosed |
| WO-2006023852-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079505-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | CYP2D6 1646/4885DRD2 757/4885DRD4 1562/4885 |
| US-20130281476-A1 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | CYP2D6 1646/4885DRD2 757/4885DRD4 1562/4885 |
| US-20060270653-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | CYP2D6 1646/4885DRD2 757/4885DRD4 1562/4885 |
| US-20070043023-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | CYP2D6 1646/4885DRD2 757/4885DRD4 1562/4885 |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | CHRM3, CHRM2, CHRM5 | CYP2D6 1135/4885DRD2 491/4885DRD4 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.